0000000000325514

AUTHOR

Dariusz Wojciechowski

showing 2 related works from this author

Incidence of severe critical events in paediatric anaesthesia (APRICOT): a prospective multicentre observational study in 261 hospitals in Europe

2017

Background Little is known about the incidence of severe critical events in children undergoing general anaesthesia in Europe. We aimed to identify the incidence, nature, and outcome of severe critical events in children undergoing anaesthesia, and the associated potential risk factors. Methods The APRICOT study was a prospective observational multicentre cohort study of children from birth to 15 years of age undergoing elective or urgent anaesthesia for diagnostic or surgical procedures. Children were eligible for inclusion during a 2-week period determined prospectively by each centre. There were 261 participating centres across 33 European countries. The primary endpoint was the occurenc…

MalePediatricsHealth StatusOPERATING-ROOMRespiratory Tract DiseasesCHILDREN0302 clinical medicineREGIONAL ANESTHESIAPostoperative Complications030202 anesthesiologyCARDIAC-ARRESTMedicineGeneral anaesthesiaProspective StudiesProspective cohort studyChildIntraoperative ComplicationsCOMPLICATIONSddc:617Incidence (epidemiology)Mortality ratemusculoskeletal neural and ocular physiologyIncidenceAge FactorsHospitalsEuropeCardiovascular DiseasesChild PreschoolRESPIRATORY ADVERSE EVENTSFemaleClinical CompetenceCohort studyPulmonary and Respiratory Medicinemedicine.medical_specialtyAdolescentmacromolecular substancesAnesthesia GeneralDrug Hypersensitivity03 medical and health sciencesMORBIDITYJournal ArticleHumansbusiness.industryInfant NewbornInfant030208 emergency & critical care medicinePerioperativenervous systemPROSPECTIVE COHORTRelative riskRISK-FACTORSObservational studyHuman medicineNervous System DiseasesbusinessSYSTEM
researchProduct

A new approach to ticagrelor-based de-escalation of antiplatelet therapy after acute coronary syndrome. A rationale for a randomized, double-blind, p…

2021

The risk of ischemic events gradually decreases after acute coronary syndrome (ACS), reaching a stable level after 1 month, while the risk of bleeding remains steady during the whole period of dual antiplatelet treatment (DAPT). Several de-escalation strategies of antiplatelet treatment aiming to enhance safety of DAPT without depriving it of its efficacy have been evaluated so far. We hypothesized that reduction of the ticagrelor maintenance dose 1 month after ACS and its continuation until 12 months after ACS may improve adherence to antiplatelet treatment due to better tolerability compared with the standard dose of ticagrelor. Moreover, improved safety of treatment and preserved anti-is…

Acute coronary syndromemedicine.medical_specialtyELECTRA-SIRIO 2TicagrelorClinical CardiologyPlaceboantiplatelet therapylaw.inventionacute coronary syndrometicagrelorClinical studyPercutaneous Coronary InterventionRandomized controlled triallawInternal medicinemedicineHumansAcute Coronary SyndromeAspirinbusiness.industryMaintenance doseGeneral Medicinemedicine.diseasede-escalationTolerabilityELECTRA-SIRIO 2 ; acute coronary syndrome ; antiplatelet therapy ; de-escalation ; ticagrelorCardiologyCardiology and Cardiovascular MedicinebusinessTicagrelorDe-escalationPlatelet Aggregation Inhibitorsmedicine.drug
researchProduct